Larotrectinib Achieves Rapid, Durable Responses in TRK Fusion-Positive CNS Tumors
Recorded Courses
hosted byProjects In Knowledge Inc. (PIK)
hosted byProjects In Knowledge Inc. (PIK)
attend it anywhere online
category
Medicine, Nursing, Pharmacy, Healthcare Management
Oncology, Neurology, Pathology
price
Free
Larotrectinib Achieves Rapid, Durable Responses in TRK Fusion-Positive CNS Tumors is organized by Projects In Knowledge Inc. (PIK).
Activity Goal:
The goal of this activity series is to provide expert commentary and analysis on current and emerging management strategies in CNS tumors.
Learning Objective(s):
Analyze the most recent clinical trial data regarding newly FDA-approved TRK inhibitors for the treatment of primary CNS cancers.
Integrate TRK inhibitors into evolving CNS tumor treatment paradigms.
Additional details will be posted as soon as information is available.